Shareholders approved a share consolidation ratio of eight-for-one, reducing Class A and Class B ordinary shares to one-eighth of the original count with a new par value of US$0.0024. The transaction takes effect on November 13, 2026, accompanied by amendments to the memorandum and articles of association. Sangrix Inc. operates in the biotechnology sector.
